The Mitochondrial Synergy: Why SS-31 Must Precede MOTS-c for Maximum Effect

The Mitochondrial Ageing Cascade

Mitochondrial dysfunction is central to the ageing process. But it is not a single event — it is a cascade involving two distinct and compounding problems:

Problem 1 — Structural degradation: Cardiolipin oxidation → cristae unfolding → ETC complex dissociation → electron leakage → ROS overproduction → further cardiolipin oxidation. This is the structural problem, addressed by SS-31.

Problem 2 — Quantity decline: With age, mitochondrial biogenesis declines while mitophagy (mitochondrial degradation) is impaired. The result is a shrinking pool of increasingly dysfunctional mitochondria. This is the quantity problem, addressed by MOTS-c.

Both problems require simultaneous attention — but in the right order.

Why Sequencing Matters: The Template Principle

This is the mechanistic core of the protocol. Mitochondrial biogenesis works through fission, fusion, and de novo synthesis — but new mitochondria are assembled using components and membrane material from existing mitochondria. The existing mitochondrial population serves as a template for biogenesis.

If you activate biogenesis (MOTS-c) on a structurally compromised mitochondrial population — degraded cardiolipin, collapsed cristae, dissociated ETC complexes — the new mitochondria are built using these defective components as templates. You end up with more mitochondria, but they inherit the structural deficiencies of the parent population.

SS-31 first restores cardiolipin integrity and cristae structure. ^[] The existing mitochondrial population is now structurally sound. MOTS-c then drives biogenesis from this corrected template — producing new mitochondria that inherit the restored architecture. ^[]

The 2-hour gap between SS-31 and MOTS-c allows SS-31 to be distributed and begin membrane stabilisation before the biogenesis signal arrives.

The Four-Layer Protocol

Layer 1 — SS-31 (Structural repair): 20mg SC at 8am. Targets cardiolipin, restores cristae, reduces ROS production.

Layer 2 — MOTS-c (Biogenesis): 10mg SC at 10am. Activates AMPK, drives PGC-1α and mitochondrial biogenesis. The 2-hour delay allows SS-31 to establish the structural template.

Layer 3 — NMN (NAD+ substrate): 500mg oral at 8am with SS-31. Provides the NAD+ substrate that a restored ETC can now utilise efficiently. A repaired electron transport chain with abundant NAD+ produces maximum ATP output.

Layer 4 — PQQ (Biogenesis amplification): 20mg oral at 8am. Activates PGC-1α independently of MOTS-c, providing additive biogenesis stimulus. Also acts as a redox cofactor, complementing SS-31's ROS reduction.

Clinical Context: Who Benefits Most

This protocol is most relevant for:

• Chronic fatigue syndrome / ME-CFS: Mitochondrial dysfunction is a primary proposed mechanism
• Post-viral fatigue (Long COVID): Mitochondrial damage is documented in COVID-19 pathophysiology
• Age-related performance decline: Progressive mitochondrial dysfunction is a major contributor
• Exercise performance optimisation: Mitochondrial density and efficiency are primary determinants of VO2max

Monitoring: track subjective energy, exercise performance (VO2max, power output), and optionally plasma lactate at submaximal exercise intensities — an indirect marker of mitochondrial efficiency.